Abattis Bioceuticals Corp.
ATTBF
$0.00
$0.000.00%
| 09/30/2019 | 06/30/2019 | ||||
|---|---|---|---|---|---|
| Revenue | 79.37% | 5,868.75% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 79.37% | 5,868.75% | |||
| Cost of Revenue | 26.56% | -- | |||
| Gross Profit | 115.06% | 3,468.75% | |||
| SG&A Expenses | -25.23% | -20.86% | |||
| Depreciation & Amortization | 120.75% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -18.79% | -15.61% | |||
| Operating Income | 35.11% | 27.51% | |||
| Income Before Tax | -29.12% | -409.42% | |||
| Income Tax Expenses | -202.63% | -- | |||
| Earnings from Continuing Operations | -27.49% | -413.06% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -24.89% | -413.06% | |||
| EBIT | 35.11% | 27.51% | |||
| EBITDA | 34.59% | 28.07% | |||
| EPS Basic | -16.67% | -500.00% | |||
| Normalized Basic EPS | 114.29% | 30.00% | |||
| EPS Diluted | -16.67% | -500.00% | |||
| Normalized Diluted EPS | 114.29% | 30.00% | |||
| Average Basic Shares Outstanding | 0.02% | 0.03% | |||
| Average Diluted Shares Outstanding | 0.02% | 0.03% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
